Thymosin Alpha-1 Research Guide

Full name: Thymosin Alpha-1 (Thymalfasin)

A thymic peptide approved in over 35 countries for immune modulation. Enhances T-cell function, dendritic cell maturation, and anti-viral/anti-tumor immunity without overstimulation.

How Thymosin Alpha-1 Works

Activates toll-like receptors (TLR2, TLR9) on dendritic cells, promotes T-cell maturation and differentiation, enhances NK cell cytotoxicity, and modulates cytokine profiles.

Dosing Protocol

• Typical dose: 1.6-3.2 mg
• Frequency: 2-3x per week
• Duration: 4-12 weeks or longer
• Route: Subcutaneous injection

Reported Benefits

• Enhanced T-cell immunity
• Anti-viral activity
• Dendritic cell activation
• Cancer immunosurveillance
• Vaccine adjuvant effects

Potential Side Effects

• Injection site discomfort
• Mild fatigue
• Low-grade fever (rare)
• Muscle aches

Research Citations

1. Thymalfasin in hepatitis B treatment (2019) - Improved sustained virologic response rates by 25% when combined with standard antiviral therapy.
2. Thymosin alpha-1 immune modulation in COVID-19 (2021) - Reduced mortality and improved T-cell counts in severe COVID-19 patients as adjunctive therapy.

Related Immune Support Compounds

• Thymulin - Full Profile
• Lactoferrin - Full Profile
• Beta-Defensin - Full Profile
• TA1 - Full Profile
• Thymalin - Full Profile
• Vitamin D3 Injection - Full Profile

View full Thymosin Alpha-1 profile with 3D molecule viewer →